{
    "clinical_study": {
        "@rank": "109474", 
        "brief_summary": {
            "textblock": "To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who\n      are unable to take the three commercially available protease inhibitors (because of failure,\n      intolerance, or contraindication) and who have a CD4 cell count of <= 50. To obtain\n      additional information on the safety profile of nelfinavir mesylate (Viracept).\n\n      (PER AMENDMENT 1/8/97: People now qualify for the Viracept Program if they are unable to\n      take indinavir and/or ritonavir due to intolerance, contraindication or prior failure.)"
        }, 
        "brief_title": "Viracept Expanded Access Program", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  CD4 T cell count <= 100 cells/mm3.\n\n          -  Failed, been intolerant of or had a contraindication to all three commercially\n             available protease inhibitors (saquinavir, indinavir and ritonavir).\n\n        (PER AMENDMENT 1/8/97:\n\n          -  People now qualify for the Viracept Program if they are unable to take indinavir\n             and/or ritonavir due to intolerance, contraindication or prior failure.)\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n        Prior therapy with Viracept.\n\n        Required:\n\n          -  Indinavir.\n\n          -  Saquinavir.\n\n          -  Ritonavir."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002165", 
            "org_study_id": "259B", 
            "secondary_id": [
                "Study 515", 
                "AG1343 - 515"
            ]
        }, 
        "intervention": {
            "intervention_name": "Nelfinavir mesylate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Nelfinavir"
            ]
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "HIV Protease Inhibitors", 
            "CD4 Lymphocyte Count", 
            "Nelfinavir", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92121"
                }, 
                "name": "Agouron Pharmaceuticals Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Viracept Expanded Access Program", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "11363981", 
            "citation": "[No authors listed] New protease inhibitor available through expanded access. Posit Aware. 1996 Nov-Dec;7(6):7. No abstract available."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002165"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Agouron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1996"
    }, 
    "geocoordinates": {
        "Agouron Pharmaceuticals Inc": "32.715 -117.157"
    }
}